SLC5A2 and type 2 diabetes mellitus: Furthermore, to our knowledge, only very few clinical trials have investigated whether SGLT2 inhibitors protect against atherosclerosis in subjects with T2DM but no apparent cardiovascular disease (CVD) [10].